{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-024826","form_type":"8-K","ticker":"ONCO","cik":"0001782107","company_name":"Onconetix, Inc.","filed_at":"2025-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.832992+00:00","generated_at":"2026-05-24T11:56:49.987494+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Onconetix to present Proclarix clinical data at EAU congress; study of 800+ patients","bullets":["Abstract accepted for 2025 European Association of Urology congress (March 21-24, Madrid).","Presentation titled 'Clinical Performance of Proclarix in Ruling Out Clinically Insignificant or No Prostate Cancer.'","Study includes >800 patients from Lillebaelt Hospital, University Hospital of Southern Denmark.","Proclarix is a biomarker-based blood test; CEO notes potential to reduce biopsies.","No financial terms disclosed; presentation scheduled March 23."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-024826","json":"https://secwatch.observer/filing/0001213900-25-024826.json","markdown":"https://secwatch.observer/filing/0001213900-25-024826.md","text":"https://secwatch.observer/filing/0001213900-25-024826.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782107/000121390025024826/0001213900-25-024826-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782107/000121390025024826/ea0234883-8k_onconetix.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T11:56:49.987494+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}